Generating functionally stable and antigen-specific Treg cells from effector T cells for cell therapy of inflammatory

Norihisa Mikami1, Ryoji Kawakami2, Atsushi Sugimoto1

  • 1Department of Experimental Immunology, Immunology Frontier Research Center, The University of Osaka, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.

PubMed

One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T (Tconv) cells into Foxp3+ regulatory T (Treg) cells that are as stably suppressive as naturally occurring Treg (nTreg) cells. To achieve the conversion in vitro for mice and humans, we induced high Foxp3 expression in antigen- and interleukin-2 (IL-2)-stimulated Tconv cells by CDK8/19 inhibition. We further established Treg cell-specific epigenetic changes by depriving CD28 costimulation during in vitro Treg cell induction to specifically promote the expression of Treg cell signature genes, especially Foxp3. Repeating this process, with intermittent resting cultures containing IL-2 only, enabled efficient conversion of naïve as well as effector/memory CD4+ Tconv cells, including T helper 1 (TH1), TH2, and TH17 cells, into Foxp3+ Treg cells. These induced Treg (iTreg) cells were similar to nTreg cells in transcription and epigenetic modification and were functionally and phenotypically stable in vivo. Moreover, they effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory Tconv cell-derived, functionally stable, iTreg cells may represent a strategy to achieve antigen- and disease-specific treatment of immunological diseases.